Inotek Pharmaceuticals Corp. RCKT 深 沪
等待开盘 07-30 09:30:00 美东时间
3.01
-0.100
-3.22%
华盛通- 最 高3.14
- 今 开3.12
- 成交量 160.63万股
- 最 低 3.00
- 昨 收 3.11
- 总市值 3.25亿
- 52周最高 22.01
- 市盈率 静 --
- 换手率 1.49%
- 52周最低 2.19
- 委 比 -78.82%
- 总股本 1.08亿
- 历史最高 67.48
- 量 比 0.48
- 振 幅 4.50%
- 历史最低 2.19
- 每 手 1
- 风险率 4.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅102.43%！Mobileye Global获Canaccord Genuity升目标价至30美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Mobileye Global"买入"评级，目标价从25美元升至30美元；巴克莱：维持TechnipFMC"超配"评级，目标价从45美元升至51美元
07-28 09:33
Rocket Refocuses Pipeline As Gene Therapy Sentiment Sours
Rocket Pharmaceuticals downgraded by BofA after FDA halts Danon disease trial; company pivots toward earlier-stage gene therapy programs.
07-26 03:02
美股大行评级 | DA Davidson上调谷歌目标价从160美元升至180美元；波士顿科学获三家大行上调目标价
今日重点评级关注：Lake Street：维持BlackSky Technology"买入"评级，目标价从18美元升至28美元；瑞杰金融：维持SEI Investments"跑赢大市"评级，目标价从115美元升至118美元
07-25 09:35
Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $12
Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and lowers the price target from $17 to $12.
07-25 06:36
Rocket Pharmaceuticals cuts headcount, realigns pipeline
Rocket Pharmaceuticals (NASDAQ:RCKT) announced on Thursday that it will reduce its workforce by about 30% as part of a restructuring effort. This decision, along with other planned cost-saving initiat...
07-24 21:46
Needham Maintains Hold on Rocket Pharmaceuticalsto Hold
Needham analyst Gil Blum maintains Rocket Pharmaceuticals (NASDAQ:RCKT) from Hold to Hold.
07-24 17:53
Rocket Pharmaceuticals Announces Strategic Reorganization Plan
Rocket Pharmaceuticals ( ($RCKT) ) has issued an announcement. On July 23, 2025...
07-24 04:52
Rocket Pharmaceuticals Receives FDA RMAT Designation
Rocket Pharmaceuticals ( ($RCKT) ) has provided an announcement. On July 17, 20...
07-17 20:15
ATTENTION NASDAQ: RCKT INVESTORS: Contact Berger Montague About a Rocket Pharmaceuticals Class Action Lawsuit
PHILADELPHIA, July 15, 2025 /PRNewswire/ -- Berger Montague PC, a nationally recognized securities litigation firm based in Philadelphia, announces it is investigating a newly filed securiti...
07-16 04:06
Rocket Pharma Receives FDA Clearance For IND Application For RP-A701, Aavrh.74-Based Gene Therapy Candidate For Treatment Of BAG3-Associated Dilated Cardiomyopathy
RP-A701 is a first-in-class gene therapy for the treatment of BAG3-associated dilated cardiomyopathyBAG3-associated dilated cardiomyopathy is a rare, inherited heart condition caused by mutations in the BAG3 gene,
06-30 19:10
